Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas. (Q51214174)

1 April 2018

title

Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas. (English)

1 reference

1 April 2018

author name string

Shioto Suzuki

1

1 reference

1 April 2018

Satoshi Igarashi

2

1 reference

1 April 2018

Mitsuhiko Hanawa

3

1 reference

1 April 2018

Hirochika Matsubara

4

1 reference

1 April 2018

Akishi Ooi

5

1 reference

1 April 2018

Yoh Dobashi

6

1 reference

1 April 2018

publication date

28 April 2006

1 reference

1 April 2018

published in

Modern Pathology

1 reference

1 April 2018

volume

19

1 reference

1 April 2018

issue

7

1 reference

1 April 2018

page(s)

986-998

1 reference

1 April 2018

https://scigraph.springernature.com/pub.10.1038/modpathol.3800619

exact match

0 references

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Stats: transcriptional control and biological impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Differing Roles of Akt and Serum- and Glucocorticoid-regulated Kinase in Glucose Metabolism, DNA Synthesis, and Oncogenic Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Aberration of epidermal growth factor receptor expression in bone and soft-tissue tumors: protein overexpression, gene amplification and activation of downstream molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

STAT signaling in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by alpha platelet-derived growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800619

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/MODPATHOL.3800619

1 reference

1 April 2018

PubMed ID

16648865

1 reference

1 April 2018